tradingkey.logo
tradingkey.logo

Oryzon Gets US Patent Allowance For Vafidemstat

ReutersMar 25, 2026 6:29 AM

- Oryzon Genomics SA ORY.MC:

  • STRENGTHENS VAFIDEMSTAT PATENT PORTFOLIO WITH U.S. NOTICE OF ALLOWANCE

  • U.S. PATENT EXPECTED TO REMAIN IN FORCE UNTIL AT LEAST 2040, EXCLUDING ANY POTENTIAL PATENT TERM ADJUSTMENTS OR EXTENSIONS

  • PATENT PORTFOLIO COVERS THE USE OF VAFIDEMSTAT FOR TREATING NON-AGGRESSIVE SYMPTOMS OF BORDERLINE PERSONALITY DISORDER

Source text

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI